Zoetis Inc. (NYSE:ZTS) Shares Purchased by Amalgamated Bank

Amalgamated Bank raised its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 2.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 94,330 shares of the company's stock after purchasing an additional 1,893 shares during the quarter. Amalgamated Bank's holdings in Zoetis were worth $15,531,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. Rakuten Securities Inc. lifted its stake in Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after acquiring an additional 166 shares in the last quarter. Navigoe LLC purchased a new stake in Zoetis during the fourth quarter worth about $30,000. Murphy & Mullick Capital Management Corp acquired a new stake in shares of Zoetis during the fourth quarter worth about $44,000. Sound Income Strategies LLC boosted its stake in shares of Zoetis by 141.4% in the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after purchasing an additional 164 shares during the period. Finally, Bfsg LLC boosted its stake in shares of Zoetis by 614.6% in the first quarter. Bfsg LLC now owns 293 shares of the company's stock valued at $48,000 after purchasing an additional 252 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the company's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the transaction, the executive vice president owned 15,129 shares in the company, valued at $2,571,930. This represents a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by company insiders.

Zoetis Trading Down 0.2%

ZTS opened at $155.86 on Tuesday. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.04 and a current ratio of 1.74. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The company has a market cap of $69.39 billion, a P/E ratio of 27.98, a PEG ratio of 2.59 and a beta of 0.94. The business's 50-day simple moving average is $160.58 and its 200-day simple moving average is $162.36.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The company had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. During the same period in the prior year, the firm posted $1.38 earnings per share. The firm's revenue was up 1.4% on a year-over-year basis. As a group, equities research analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 annualized dividend and a yield of 1.28%. Zoetis's dividend payout ratio is currently 35.91%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on ZTS shares. Piper Sandler increased their target price on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Monday, May 12th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and cut their price objective for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Wall Street Zen upgraded Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Finally, UBS Group cut their price target on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $212.13.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.